Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Girentuximab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Girentuximab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Girentuximab. |
| Estrone | Estrone may increase the thrombogenic activities of Girentuximab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Girentuximab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Girentuximab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Girentuximab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Girentuximab. |
| Estriol | Estriol may increase the thrombogenic activities of Girentuximab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Girentuximab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Girentuximab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Girentuximab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Girentuximab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Girentuximab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Girentuximab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Girentuximab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Girentuximab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Girentuximab. |
| Equol | Equol may increase the thrombogenic activities of Girentuximab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Girentuximab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Girentuximab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Girentuximab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Girentuximab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Girentuximab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Girentuximab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Girentuximab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Girentuximab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Girentuximab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Girentuximab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Girentuximab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Girentuximab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Girentuximab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Girentuximab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Girentuximab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Girentuximab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Girentuximab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Girentuximab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Girentuximab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Girentuximab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Girentuximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Girentuximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Girentuximab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Girentuximab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Girentuximab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Girentuximab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Girentuximab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Girentuximab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Girentuximab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Girentuximab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Girentuximab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Girentuximab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Girentuximab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Girentuximab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Girentuximab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Girentuximab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Girentuximab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Girentuximab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Girentuximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Girentuximab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Girentuximab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Girentuximab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Girentuximab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Girentuximab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Girentuximab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Girentuximab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Girentuximab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Girentuximab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Girentuximab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Girentuximab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Girentuximab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Girentuximab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Girentuximab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Girentuximab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Girentuximab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Girentuximab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Girentuximab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Girentuximab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Girentuximab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Girentuximab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Girentuximab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Girentuximab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Girentuximab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Girentuximab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Canakinumab. |